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Abstract
Introduction As primary hyperparathyroidism aVects
mainly middle-aged and elderly women, it is an infrequent
Wnding during gestation and breastfeeding. To date, less than
200 pregnant patients with primary hyperparathyroidism
diagnosed during pregnancy have been described. Like in
other disorders of the parathyroid gland, the recognition of
primary hyperparathyroidism during pregnancy and lactation
may be diYcult, as clinical symptoms are not speciWc, while
laboratory Wndings may be masked by some typical preg-
nancy-induced changes in calcium and phosphate homeosta-
sis. If remains untreated, the disease may result in serious
clinical implications for the mother and fetus. Most authors
consider surgery within the second trimester of pregnancy as
the treatment of choice in this group of patients.
Case report  In our paper, we discuss the case of a
35-year-old female with a history of recurrent acute pancreati-
tis and recurrent abortions. As the patient declined surgery,
conservative management with calcitonin was started and
continued throughout the rest of pregnancy, and led to giving
birth to the infant whose only health problem was transient
hypocalcemia.
Conclusion  The described case shows that conservative
management, if started respectively early and conducted on
the basis of a patient’s condition, may eVectively reduce
increased perinatal and maternal morbidity and mortality in
pregnant women declining surgery.
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Introduction
In the general population, primary hyperparathyroidism is
considered a common disorder. Its greatest frequency is
observed in postmenopausal women, in whom it reaches a
prevalence of 2–3% [1]. The most frequent cause of pri-
mary hyperparathyroidism in the general population is a
single parathyroid adenoma (85%), followed by parathy-
roid hyperplasia (15–20%) and, albeit very rarely (less than
1%), by carcinoma [2, 3]. Interestingly, less than 200 of
patients with primary hyperparathyroidism have been
described in gestation and during the postpartum period
[4–6]. This relative paucity of data may be explained by at
least three diVerent causes. Firstly, the average age of the
initial manifestation of this disorder is higher than that of
women of childbearing age [1–3]. Second, about 80% of
non-pregnant individuals with hyperparathyroidism are
characterised by an asymptomatic course of this disease [5].
And Wnally, some symptoms of primary hyperparathyroid-
ism may be misinterpreted as a simple consequence of
pregnancy or other gestation-related disorders, while physi-
ological changes during gestation may mask some abnor-
malities typical to primary hyperparathyroidism [4, 7].
What is worth mentioning is that compared to the remain-
ing subjects, pregnant ones with primary hyperparathyroid-
ism often experience a clinically overt course of this
disease [5, 6]. Making the correct diagnosis of primary
hyperparathyroidism in pregnancy is regarded crucial,
because if this disorder remains unrecognized and left
untreated, it may pose a signiWcant risk to the mother and
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maternal morbidity and mortality [6, 8].
This article shows the case of a young woman with three
spontaneous abortions, in whom primary hyperparathyroid-
ism was diagnosed for the Wrst time during fourth gestation.
In the paper, we present diagnostic and treatment dilemmas
associated with Wnding and treatment of this disorder dur-
ing gestation. We describe in detail treatment strategies
undertaken in this patient and their impact on the outcome
of pregnancy and lactation.
Clinical picture
A 35-year-old woman was admitted to the gastroenterologi-
cal ward in the eighth week of her fourth pregnancy because
of a strong abdominal pain, nausea, vomiting and anorexia.
All her previous pregnancies ended in spontaneous miscar-
riages in the, respectively, tenth, eighth and sixth week of
gestation. During the last one, taking place a year before the
present admission, the abortion was preceded by laboratory-
conWrmed acute pancreatitis. In the second gestation, she
experienced similar symptoms of a strong periumbilical pain
and vomiting. These symptoms, which occurred a week
before pregnancy termination and treated without broadening
diagnosis, retrospectively suggested the presence of pancrea-
titis. On admittance to the gastroenterological ward, the
patient presented symptoms of dehydratation. She was
asthenic, had dry skin and mouth. The thyroid gland was not
palpable and there was no galactorrhea. Abdomen was dis-
tended and the bowel sounds were absent. The liver was
slightly enlarged (2 cm below the costal margin). Uterine
size corresponded to the period of gestation. Blood pressure
was reduced (90/65 mmHg), heart rate was 104 beats/min,
while temperature was elevated (and 38.2°C). She had no
history of gestational diabetes mellitus, alcohol use, oral con-
traception pills, gallstones or drug intake. Initial laboratory
investigations revealed increased amylasaemia (825 U/L;
normal values <150 U/L) and lipasaemia (980 U/L; normal
values <150 U/L), increased urine amylase content (420 U/L;
normal range 8–12 U/L), hyperglycemia (7.4 mmol/L),
increased leucocyte count (19,800/mm-3), increased CRP
levels (122 mg/L; normal values <5 mg/L) and a hematocrit
of 47.8%. Lipid proWle and liver and renal function tests
(plasma activity/levels of alanine aminotransferase, aspartate
aminotransferase, -glutamyl transpeptidase, total bilirubin,
creatinine and urea nitrogen) were within normal limits. On
ultrasound the patient had oedematous pancreatitis with
irregular pancreatic outline, and a small amount of peripan-
creatic Xuid as well as bilateral massive nephrolithiasis with-
out evidence of cholelithiasis. Computed tomography was
not performed (contraindicated in pregnancy), and the patient
did not undergo magnetic resonance imaging examination
due to a suggestive clinical picture and the lack of agreement
(a fear of thermal damage of fetal tissues). The patient was
diagnosed with acute pancreatitis without systemic complica-
tions (Ranson’s score 2, APACHE II score 4, BISAP 1) and
treated conservatively with fasting, narcotic analgesia (pethi-
dine 50 mg subcutaneously every 6 h for the Wrst 24 h) and
intravenous Xuids. Because of concomitant asymptomatic
bacteriuria she also received cefuroxime (750 mg intramus-
cularly every 8 h for 5 days). Although during this treatment
her physical condition has markedly improved, initially high-
normal calcaemia (plasma calcium levels corrected for
albumin 2.6 mmol/L; normal values 2.2–2.6 mmol/L, ionized
calcium 1.3 mmol/L; normal values 0.9–1.3 mmol/L) started
to grow reaching on day 4 the following values: total calcium
3.2 mmol/L, ionized calcium 1.7 mmol/L. This was accom-
panied by hypophosphatemia 0.7 nmol/L (normal values
0.9–1.5 mmol/L) and therefore the patient was transferred to
our unit. On admittance to our ward she had elevated plasma
intact PTH assessed using immunoradiometric assay
(130 ng/L; normal values 15–75 ng/L), while 25-hydroxyvi-
tamin D plasma levels (25 nmol/L) were within the normal
limits (15–80 nmol/L). The levels of serum amylase and
lipase were within the reference values. Because of the preg-
nancy we did not decide on the measurement of alkaline
phosphatase, is increased during normal gestation. No abnor-
malities in plasma levels of thyrotropin, free thyroxine and
free triiodothyronine were observed. As these results sug-
gested the presence of primary hyperpararthyroidism, we
introduced intavenous infusions of saline and the patient was
managed with salmon calcitonin (at the dose of 4 mg/kg
administered intramuscularly every 8 h; 12 doses), which is
more potent and longer acting than the human hormone. We
also suggested that the patient should undergo surgical inter-
vention, preferably in the second trimester of pregnancy, as a
radical treatment. After informing the patient about beneWts
and risks associated with the procedure, she declined this
form of therapy during pregnancy, agreeing on its perfor-
mance after delivery. Calcitonin treatment resulted in a clini-
cal improvement and quick resolving of hypercalcemia,
while ultrasonography revealed normal fetal development
without growth retardation, the patient was discharged from
hospital on twelfth week of pregnancy and recommended to
monitor plasma calcium and phosphate levels on a weekly
basis. She was advised to take about 4 L of Xuids daily to
increase calcium excretion. In case of symptoms of hypercal-
cemia (constipations, proximal muscle weakness, fatigue,
anorexia, abdominal pains, depression or any cognitive dis-
function) or increased plasma calcium levels exceeding
2.8 mmol/L she was suggested to contact our department to
modify hypercalcemia treatment. Between weeks 12 and 32
she periodically experienced constipations or muscle weak-
ness, which were accompanied by an increase in plasma cal-
cium levels and resolved after intramuscular injections of123
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times. Because since week 32, the need of calcitonin admin-
istration became more evident (between weeks 32 and 34 she
had to receive calcitonin twice a week with only partial clini-
cal response), we decided to recommend our patient 3 g of
oral phosphates, which resulted in a lowering calcium levels
and increasing phosphate levels to the values observed in
healthy subjects. The gestation ended in the 38th week with
spontaneous vaginal delivery. A live-born infant (3,250 g,
52 cm) had Apgar score of 9 without any malformations
observed on physical examination. The infant was found,
however, to have hypercalcemia (2.9 mmol/L) immediately
after birth. Initially increased calcium levels started to
decrease in the following days reaching on neonatal day 6 the
value of 1.9 mmol/L. Because of the risk of symptomatic
hypoparathyroidism we started intravenous calcium infusion
(400 mg/kg/day of calcium gluconate), which led to a nor-
malisation of plasma calcium during 6 h. The infusion was
continued for the 4 following days, since neonate day 8 with
gradually reduced rate and on day 10 it was Wnally discontin-
ued. The child had no other health problems related to pri-
mary hyperpaprathyroidism and therefore was discharged
from hospital on day 14. Subsequent follow ups revealed its
normal development. Cervical computed tomography, per-
formed 2 months after delivery, revealed the presence of a
nodule located posteriorly to the upper part of the left thyroid
lobe, in which 99 mTc-sestamibi was clearly accumulated.
Three months after delivery, the patient underwent surgery
for the excision of this tumor. Since delivery to the time of
operation the subject did not need to be given calcitonin or
phosphates and her calcium levels were slightly elevated
(total calcium 2.9 mmol/L, ionized calcium 1.5 mmol/L. His-
tological examination of the removed tissue conWrmed the
presence of a benign adenoma of the parathyroid gland.
Because of nephrolithiasis, 6 month after delivery she under-
went lithotripsy. Two years later, the patient became preg-
nant for the Wfth time. The course of this pregnancy was
uneventful and ended in a spontaneous delivery in 40 week,
with no abnormalities in the infant.
Discussion
Pregnancy and lactation are characterized by important
alterations in calcium homeostasis, being a consequence of
pregnancy-induced changes in the synthesis, metabolism
and excretion of calcium and calcitropic hormones [4, 9].
For these reasons clinical manifestations of parathyroid dis-
orders in pregnancy are often diVerent from those observed
in non-pregnant women. As the symptoms experienced by
patients with parathyroid disorders are not speciWc, their
diagnosis during gestation and breastfeeding may be some-
times very diYcult [4, 9]. Unfortunately this was the case in
our patient, whose three previous pregnancies, because of
the presence of unrecognized parathyroid pathology, ended
in intrauterine fetal demise, which in two pregnancies was
preceded by documented intrauterine growth retardation.
These results clearly indicate that primary hyperparathy-
roidism, if remains undiagnosed and consequently
untreated, is associated with a markedly increased risk of
pre- and perinatal mortality.
The data obtained from analysis of so far described cases
indicate that in opposition to the general population, 4 of
every 5 hyperparathyroid pregnant patients experience clin-
ical manifestations of this disorder. The most frequent of
them, observed also in our patient, was the presence of
nephrolithiasis [5]. The initiation and growth of kidney cal-
culi may be attributed to overlapping of both increased cal-
cium load, secondary to enhanced PTH synthesis and
release, and a pregnancy-induced increase in urine calcium
excretion (a typical symptom of physiological pregnancy).
The large size of concrements in our patient may be
explained by her undergoing several pregnancies during a
relative short period of time.
However, the most characteristic health problem experi-
enced by the patient was recurrent acute pancreatitis. Inter-
estingly, the frequency of this complication in pregnancy-
related primary hyperparathyroidism is higher (7–13%)
than in hyperparathyroidism taking place in non-pregnant
individuals (1–2%) [5, 10, 11]. The fact that pancreatitis
was present in three of four pregnancies complicated by
hyperparathyroidism, while never occurred before and
between pregnancies, supports these statistical data that
gestation makes hyperparathyroid patients particularly
prone to the development of this complication. It is
assumed that pancreatitis occur more frequently in primip-
aras than in women who underwent multiple pregnancies
and occurs mainly in the Wrst and third trimester of gesta-
tion [6, 12]. Our observations only partially support these
data. Although all cases of pancreatitis in our subject
occurred in the Wrst trimester, they were observed in several
following pregnancies. Albeit gestation by itself may be
associated with primary hyperparathyroidism of pregnancy,
such a situation probably did not take place in the described
patient. We think so because this complication did not
develop in her last pregnancy, which occurred after remov-
ing the adenoma.
Although the treatment of choice in primary hyperpara-
thyroidism is the surgical intervention performed prefera-
bly during the second trimester of pregnancy, the patient
declined this option of treatment because of the fear of
potential complications to the fetus [12, 13]. Parathyroidec-
tomy in pregnancy is associated with a slightly increased
risk of a spontaneous abortion [12, 13]. Respecting the
choice of the patient, we decided on calcitonin administration.
This agent is considered the safest conservative treatment123
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safety of calcitonin during gestation probably results from
its negligible passage through the placenta [14, 15]. The
choice of this agent was also supported by suggested but
not fully supported beneWcial eVects of calcitonin in the
management of pancreatitis observed in non-pregnant sub-
jects [16]. Although presently no parameters are known that
may predict the outcome of primary hyperparathyroidism,
in order to limit the risk of serious complications, most pro-
fessionals recommend maintaining total plasma calcium at
the level lower than 3.0 mmol/L [17]. Exceeding this level
we considered an indication for calcitonin administration.
Interestingly, although calcitonin treatment may be associ-
ated with the development of tachyphylaxis [18], only ten-
dency to tachyphylaxis was observed in our patient in the
third trimester, and it disappeared after introduction of oral
phosphates. This fact may be explained by administration
of this agent only if plasma calcium levels exceeded the
established threshold. Moreover, the patient did not experi-
ence nausea, vomiting, diarrhea, Xushing, injection site
reactions and any other side eVects associated with calcito-
nin treatment [18]. Although some animal studies sug-
gested low birth weight in oVsprings of dams treated during
pregnancy with high doses of calcitonin [16] this was not
the case in our patient, whose infant’s birth mass was
within normal limits. Interestingly, recently Horjus et al.
[17] have shown the beneWts of combined administration of
calcitonin and cinacalcet in pregnancy and puerperium.
Because this treatment option was inaccessible for us, we
cannot support the utility of this calcimimetic in hyperpara-
thyroid pregnant women.
The only symptom experienced by the neonate after
delivery was transient hypocalcemia, which disappeared
shortly after the beginning of intravenous calcium adminis-
tration. The presence of transient mild hypocalcemia, prob-
ably resulted from increased calcium levels in fetal plasma,
inhibiting parathyroid PTH synthesis and release during the
pregnancy [14, 15, 19]. Interestingly, neonatal hypocalce-
mia was absent in the patient’s subsequent pregnancy, tak-
ing place after parathyroidectomy, which supports the
recommendations that surgery should be considered the
treatment of choice in young hyperparathyroid pregnant
women or desiring pregnancy [12, 13]. The eVectiveness of
surgical intervention in the prevention of fetal and neonatal
complications clearly indicates that hyperparathyroidism, if
successfully treated, cannot be regarded as a contraindica-
tion for consecutive pregnancies.
Summing up, the described case of our patient indicates that
pregnant women with recurrent spontaneous abortions should
be diagnosed for the presence of primary hyperparathyroidism.
It also shows that in patients declining surgery, calcitonin,
administered if needed, together with phosphates should be
considered as a treatment option for this disorder, because
of its eVectiveness and accepted safety.
ConXict of interest The authors declare that they have no conXict of
interest.
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution Noncommercial License which permits any
noncommercial use, distribution, and reproduction in any medium,
provided the original author(s) and source are credited.
References
1. Fraser WD (2009) Hyperparathyroidism. Lancet 374:145–158
2. Rodgers SE, Lew JI, Solórzano CC (2008) Primary hyperparathy-
roidism. Curr Opin Oncol 20:52–58
3. Silverberg SJ, Bilezikian JP (2006) The diagnosis and manage-
ment of asymptomatic primary hyperparathyroidism. Nat Clin
Pract Endocrinol Metab 2:494–503
4. Kovacs CS, El-Hajj Fuleihan G (2006) Calcium and bone disor-
ders during pregnancy and lactation. Endocrinol Metab Clin North
Am 35:21–51
5. Schnatz PF, Curry SL (2002) Primary hyperparathyroidism in
pregnancy: evidence-based management. Obstet Gynecol Surv
57:365–376
6. Mestman JH (1998) Parathyroid disorders of pregnancy. Semin
Perinatol 6:485–496
7. Murray JA, Newman WA 3rd, Dacus JV (1997) Hyperparathy-
roidism in pregnancy: diagnostic dilemma? Obstet Gynecol Surv
52:202–205
8. Kort KC, Schiller HJ, Numann PJ (1999) Hyperparathyroidism
and pregnancy. Am J Surg 177:66–68
9. Kohlmeier L, Marcus R (1995) Calcium disorders of pregnancy.
Endocrinol Metab Clin North Am 24:15–39
10. Inabnet WB, Baldwin D, Daniel RO, Staren ED (1996) Hyper-
parathyroidism and pancreatitis during pregnancy. Surgery
119:710–713
11. Dahan M, Chang RJ (2001) Pancreatitis secondary to hyperpara-
thyroidism during pregnancy. Obstet Gynecol 98(5 Pt 2):923–925
12. Schnatz PF, Thaxton S (2005) Parathyroidectomy in the third tri-
mester of pregnancy. Obstet Gynecol Surv 60:672–682
13. Pothiwala P, Levine SN (2009) Parathyroid surgery in pregnancy:
review of the literature and localization by aspiration for parathy-
roid hormone levels. J Perinatol 29:779–784
14. Mitchell DM, Jüppner H (2010) Regulation of calcium homeosta-
sis and bone metabolism in the fetus and neonate. Curr Opin Endo-
crinol Diabetes Obes 17:25–30
15. Kovacs CS, Kronenberg HM (1997) Maternal-fetal calcium and
bone metabolism during pregnancy, puerperium and lactation.
Endocr Rev 18:832–872
16. Wolfe HJ (1982) Calcitonin: perspectives in current concepts.
J Endocrinol Invest 5:423–432
17. Horjus C, Groot I, Telting D, van Setten P, van Sorge A, Kovacs
CS et al (2009) Cinacalcet for hyperparathyroidism in pregnancy
and puerperium. J Pediatr Endocrinol Metab 22:741–749
18. Nussbaum SR (1993) Pathophysiology and management of severe
hypercalcemia. Endocrinol Metab Clin North Am 22:343–362
19. SteVensrud S (2000) Parathyroids: the forgotten glands. Neonatal
Netw 19:9–16123
